Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
Deepcell offers an AI-powered imaging and microfluidics platform that identifies and isolates viable cells based on morphological distinctions for use in translational research, diagnostic testing, and therapeutics. It was spun out of Stanford University in 2017 and is based in Menlo Park, California. The company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 17, 2022 | Series B | $73M | 8 | Koch Disruptive Technologies | — | Detail |
Dec 7, 2020 | Series A | $20M | 6 | Bow Capital | — | Detail |
Jun 9, 2019 | Seed | — | — | — | — | Detail |
Dec 27, 2017 | Seed | $5M | 4 | Andreessen Horowitz | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Koch Disruptive Technologies | Yes | Series B |
Andreessen Horowitz | — | Series B |
Bow Capital | — | Series B |
Bridger Healthcare | — | Series B |
Casdin Capital | — | Series B |
Horizons Ventures | — | Series B |
Jeff Dean | — | Series B |
Matthew McIlwain | — | Series B |
DCVC | — | Series A |
Fifty Years | — | Series A |